From a scientific and ethical point of view there’s “no reason” to exclude lines derived earlier in embryonic development according to Lana Skirboll, who directs the NIH’s Office of Science Policy.

Skirboll says the issue came to the agency’s attention after Advanced Cell Technology Inc. (ACTC.OB), based in Worcester, Massachusetts, recently submitted for NIH approval five lines derived from blastomeres — single cells removed from morulas (which are embryos a few days old that have not yet become blastocysts).

This news, has set the stage for an upcoming development that could affect one or more of ACTC's stem cell programs as soon as next Wednesday (or sooner). Credible sources tell us the company may be making an announcement that could affect share price in a positive manner, so we wanted our subscribers to put this stock on your watchlists.

Related Story: ACTC likes new "tweaked" stem cell policy

Disclosure: Long ACTC

"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

---

Add this page to your favorite Social Bookmarking websites